Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: Description of six cases

Clinical Rheumatology

Volumn 33, Issue 5, 2014, Pages 719-723

  Theibich, Ali ^a   Dreyer, Lene ^a   Magyari, Melinda ^b   Locht, Henning ^c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

Anti TNF alpha inhibitors; Arthritis; Multiple sclerosis

Indexed keywords

ADALIMUMAB; BETA1A INTERFERON; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANKYLOSING SPONDYLITIS; ATAXIA; BLADDER DYSFUNCTION; BRAIN; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; DEMYELINATING DISEASE; DEMYELINATING NEUROPATHY; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; EVOKED SOMATOSENSORY RESPONSE; EVOKED VISUAL RESPONSE; FATIGUE; FEMALE; HEAT INTOLERANCE; HUMAN; LABORATORY TEST; MALE; MIDDLE AGED; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MUSCLE SPASM; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; OUTPATIENT DEPARTMENT; PERIPHERAL NERVOUS SYSTEM; PHYSICIAN; PLEOCYTOSIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; VISUAL DISORDER; WEAKNESS; WHITE MATTER LESION; ANTAGONISTS AND INHIBITORS; ARTHRITIS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CASE REPORT; CHEMICALLY INDUCED; COMPLICATION; INFLAMMATORY BOWEL DISEASES; OUTPATIENT; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DEMYELINATING DISEASES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; MALE; METHOTREXATE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; OUTPATIENTS; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902358938     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2419-8     Document Type: Review

References (11)

1. Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467-472
2. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457-465
3. Liu J, Marino MW, Wong G et al (1998) TNF is a potent antiinflammatory cytokine in autoimmune-mediated demyelination. Nat Med 4:78-83 (Pubitemid 28133083)
4. Tanno M, Nakamura I, Kobayshi S et al (2006) New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol 25(6):929-933 (Pubitemid 44473174)
5. Lozeron P, Denier C et al (2009) Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 66(4):490-497
6. Li SY, Birnbaum AD, Goldstein DA (2010) Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Inflamm 18(6):475-481
7. Ascherio A, Munger K (2008) Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol 28:17-28 (Pubitemid 351273081)
8. Tristano AG (2010) Neurological adverse events associated with anti-tumor necrosis factor α treatment. J Neurol 257:1421-1431
9. Fernández-Espartero MC, Pérez-Zafrilla B, Naranjo A et al (2011) Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 40:330-337
10. Winthrop KL, Chen L, Fraunfelder FW et al (2013) Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biological thERapy (SABER) study. Am J Ophthalmol 155:183-189
11. Gregory AP, Dendrou CA, Attfield KE et al (2012) TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488(7412):508-511. doi:10.1038/nature11307